retatrutide glp-1 gip glucagon triple agonist receptor Treatment with retatrutide, an agonist to GLP-1 Dual and Triple Gut Peptide
Description
J Alzheimers Dis (2018) 66(1):195218
CJC-1131, a long acting GLP-1 analog, safely normalizes post-prandial glucose excursion and fasting glycemia in type 2 diabetes mellitus [abstract]
95% CI, -0.82% to -0.13%) while maintaining stable kidney function
This new evidence about GLP-1 and vision loss has raised concerns about how well manufacturers are disclosing information and warning patients
doi: 10.1111/dom.16364
These drugs are primarily approved for treating type 2 diabetes, so coverage is usually only available if a patient with PCOS also has type 2 diabetes or obesity as a related condition
